Peak Bio, Inc.

Peak Bio, Inc. is a clinical-stage biopharmaceutical company specializing in developing therapeutics for oncology and inflammation. The company's proprietary toxin, PH-1 or Thailanstatin, is utilized to create a pipeline of novel ADC product candidates to address unmet needs in cancer patients. Their lead product candidate, PHP-303, is a small molecule undergoing Phase II dose clinical study for the orphan disease Alpha1 anti-trypsin deficiency (AATD). Peak Bio, Inc. generates revenue through the development and potential commercialization of these therapeutics, aiming to provide innovative solutions for patients in need.

Products

• Novel ADC product candidates for cancer treatment

• Small molecule PHP-303 for Alpha1 anti-trypsin deficiency